Controlled release transdermal nitroglycerin preparations provide constant plasma concentrations for up to 24 hours, offering an alternative to oral administration for patients with cardiovascular diseases.
May offer steady nitroglycerin delivery as an oral alternative; leaves open outcome trials on efficacy and tolerance.
Chronic administration of nitroglycerin may have important therapeutic effects in patients with angina, acute myocardial infarction, congestive heart failure and peripheral vascular disease. Because of unpredictable oral absorption and short duration of action, topical preparations provide an alternative mode of administration. New controlled release transdermal preparations appear to produce constant plasma nitroglycerin concentrations of 0.2-0.3 ng/ml that persist for up to 24 hours. Additional clinical trials of the therapeutic response to this drug form are necessary, particularly in regard to the relative hemodynamic efficacy and side-effect profile of sustained vs. fluctuating plasma nitroglycerin concentrations.
No takes yet. Share an insight, caveat, or question.
Olivari et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: